With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
We are looking for a Mid to Senior Front End software engineer willing to work on an exciting greenfield project: a web-based platform for surfacing the power of our AI models and state of the art data analysis methods for scientists. Our goal is to bring together world-class Scientists and Machine Learning Researchers to accelerate the discovery of therapeutic treatments for human diseases. This is an ideal role if you are passionate about the Biomedical/ Medicinal Chemistry domains, user experience, data visualisation and machine learning, and if you would be excited by the opportunity to grow your skills in these areas.
We offer a great opportunity to explore and experiment with the state of the art tech stack and product to bring it to another level. You will also have the freedom to learn more within the role through regular in-house presentations and other training and develop your career in a highly challenging, but rewarding role.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email email@example.com. Thank you.